Skip to main content

Table 1 Comparing patients under diagnostic-driven therapy with voriconazole and those under empiric antifungal therapy without voriconazole

From: Treating invasive aspergillosis in patients with hematologic malignancy: diagnostic-driven approach versus empiric therapies

Characteristics and outcomes Diagnostic-driven therapy with voriconazole Empiric antifungal therapy without voriconazole p-value
(n = 44) (n = 221)
N (%) N (%)
Age (years), median (range) 63 (23–81) 51 (14–80) < 0.001
Gender, male 26 (59) 131 (59) 0.98
Diagnosis of IA    < .001
 Definite IA 4/43 (9) 83 (38)  
 Probable IA 39/43 (91) 138 (62)  
Invasive pulmonary infectiona 40 (91) 178 (81) 0.10
Disseminated infectiona 2 (5) 18 (8) 0.41
Localized or sinus infectiona 4 (9) 28 (13) 0.51
Leukemia 19 (43) 181/220 (82) < .0001
Lymphoma 16 (36) 34/220 (15) 0.001
Myeloma 8 (18) 5/220 (2) < .001
Transplantation within 1 year prior to infection 16 (36) 82/220 (37) 0.91
Type of transplantation within prior year    0.010
 Allogeneic transplant 10/16 (63) 74/82 (90)  
 Autologous transplant 6/16 (38) 8/82 (10)  
Graft vs Host Disease (GVHD) 8/10 (80) 52/74 (70) 0.72
Neutropenia (< 500 ANC) at onset of IA 8/42 (19) 120/216 (56) < .0001
Persistent neutropenia 14/36 (39) 87/210 (41) 0.77
Received immunotherapy 10/43 (23) 154/220 (70) < .0001
Received WBC transfusion 2/42 (5) 45 (20) 0.016
Year of IA diagnosis/treatment    < .0001
 1993–2004 8 (18) 162 (73)  
 2005–2016 36 (82) 59 (27)  
Prophylactic antifungal treatment prior to 7 (16) 78 (35) 0.012
infection    
Breakthrough 6/7 (86) 67/78 (86) > .99
Response to therapy 32 (73) 30 (14) < .0001
Death within 42 days of starting therapy 2 (5) 123/220 (56) < .0001
Aspergillosis-attributable death within 42 days of starting therapy 2 (5) 107/218 (49) < .0001
  1. aOne patient had all 3 types of IA infections and 3 patients had both invasive pulmonary and localized or sinus infections